Galectin Therapeutics Inc. develops novel therapies aimed at improving the lives of patients with chronic liver diseases and cancer. Its lead drug, belapectin (GR-MD-02), is a carbohydrate-based inhibitor of the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. The primary focus of its development program is on non-alcoholic steatohepatitis (MASH) cirrhosis, a serious disease with no current cure, and the company is conducting clinical studies to evaluate its efficacy.
